COVID-19 convalescent plasma composition and immunological effects in severe patients.
COVID-19 convalescent plasma composition and immunological effects in severe patients.
复制标题
DOI：
10.1016/j.jaut.2021.102598
复制
发表时间：
2021-03
影响因子：
12.8
通讯作者：
CP-COVID-19 group
中科院分区：
文献类型：
--
作者：
Acosta-Ampudia Y;Monsalve DM;Rojas M;Rodríguez Y;Gallo JE;Salazar-Uribe JC;Santander MJ;Cala MP;Zapata W;Zapata MI;Manrique R;Pardo-Oviedo JM;Camacho B;Ramírez-Santana C;Anaya JM;CP-COVID-19 group
恢复期血浆（CP）已成为COVID-19的一种治疗方法。然而，其组成和作用机制尚不完全清楚。因此，我们进行了一项两阶段对照研究，首先评估了恢复期和重症患者的免疫学和代谢组学状态。其次，评估了CP对重症患者免疫应答的28天影响。包括19名COVID-19康复患者，18名重症住院患者和16名大流行前控制患者。患有严重疾病的患者接受CP输血和标准治疗（即，血浆受体，n = 9）或单独的标准疗法（n = 9）。在第0天和第4、7、14和28天随访期间进行临床和生物学评估。检测临床参数、病毒载量、总免疫球蛋白（IG）G和伊加抗S1-SARS-CoV-2抗体、中和抗体（NAb）、自身抗体、细胞因子、T和B细胞以及代谢组学和脂质组学特征。抗S1-SARS-CoV-2 IgG和伊加抗体是CP筛选的关键因素，并与NAb相关。在重症COVID-19患者中，大多数白细胞介素（IL）-6（P = <0.0001）、IL-10（P = <0.0001）、IP-10（P = <0.0001）、脂肪酰和甘油磷脂高于恢复期患者。在恢复期和重症患者中均观察到潜伏性自身免疫和抗IFN-α抗体。COVID-19 CP诱导了早期但短暂的细胞因子谱改变，并增加了IgG抗S1-SARS-CoV-2抗体。在输血后第28天，观察到活化的、效应的和效应记忆的CD 4+（P < 0.05）和活化的和效应的CD 8+（P < 0.01）T细胞和幼稚的B细胞（P = 0.001）减少，非经典记忆的B细胞（P=<0.0001）和中枢记忆的CD 4 + T细胞（P = 0.0252）增加。此外，与仅接受标准治疗的患者相比，血浆受体患者的IL-6/IFN-γ（P = 0.0089）和IL-6/IL-10（P = 0.0180）比值降低。这些结果可能具有治疗意义，并证明进一步的COVID-19后研究是合理的。
Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti–IFN–α antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4+ (P < 0.05) and activated and effector CD8+ (P < 0.01) T cells and naïve B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4+ T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-γ (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies.
登录
查看更多内容
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
3.2
作者：
Franco, Juan-Sebastian;Amaya-Amaya, Jenny;Anaya, Juan-Manuel
通讯作者：
Anaya, Juan-Manuel
影响因子：
20.3
作者：
Hegerova, Livia;Gooley, Ted A.;Pagel, John M.
通讯作者：
Pagel, John M.
影响因子：
8.1
作者：
Hojyo S;Uchida M;Tanaka K;Hasebe R;Tanaka Y;Murakami M;Hirano T
通讯作者：
Hirano T
DOI：
10.1007/s10096-004-1271-9
发表时间：
2005-01
期刊：
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
影响因子：
--
作者：
Cheng Y;Wong R;Soo YO;Wong WS;Lee CK;Ng MH;Chan P;Wong KC;Leung CB;Cheng G
通讯作者：
Cheng G